Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Aminopyrine breath test predicts liver-related events and death in HCV-related cirrhosis on SVR after DAA therapy.

Petta S, Rini F, Calvaruso V, Cammà C, Ciminnisi S, Di Marco V, Giannini EG, Grimaudo S, Maria Pipitone R, Craxì A.

Liver Int. 2019 Sep 11. doi: 10.1111/liv.14250. [Epub ahead of print]

PMID:
31507057
2.

Point-of-care HCV RNA testing in the setting of DAA therapy: HCV-FiS (HEpatitis C Virus Fingerstick Study).

Calvaruso V, Bronte F, Ferraro D, Reina G, Conte E, Rini F, Magro B, Petta S, Di Marco V, Craxì A.

Liver Int. 2019 Dec;39(12):2240-2243. doi: 10.1111/liv.14242. Epub 2019 Sep 20.

PMID:
31502755
3.

Is Transient Elastography Needed for Noninvasive Assessment of High-Risk Varices? The REAL Experience.

Calvaruso V, Cacciola I, Licata A, Madonia S, Benigno R, Petta S, Bronte F, Conte E, Malizia G, Bertino G, Distefano M, Montineri A, Digiacomo A, Alaimo G, Cacopardo B, Davì A, Guarneri L, Scalisi I, Colletti P, Cartabellotta F, Portelli V, Prestileo T, Averna A, Iacobello C, Mondello L, Scifo G, Russello M, Squadrito G, Raimondo G, Cammà C, Craxì A, Di Marco V; RESIST-HCV (Rete Sicilia Selezione Terapia–HCV).

Am J Gastroenterol. 2019 Aug;114(8):1275-1282. doi: 10.14309/ajg.0000000000000266.

PMID:
31135449
4.

Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.

Cabibbo G, Celsa C, Calvaruso V, Petta S, Cacciola I, Cannavò MR, Madonia S, Rossi M, Magro B, Rini F, Distefano M, Larocca L, Prestileo T, Malizia G, Bertino G, Benanti F, Licata A, Scalisi I, Mazzola G, Di Rosolini MA, Alaimo G, Averna A, Cartabellotta F, Alessi N, Guastella S, Russello M, Scifo G, Squadrito G, Raimondo G, Trevisani F, Craxì A, Di Marco V, Cammà C; Rete Sicilia Selezione Terapia – HCV (RESIST-HCV) and Italian Liver Cancer (ITA.LI.CA.) Group.

J Hepatol. 2019 Aug;71(2):265-273. doi: 10.1016/j.jhep.2019.03.027. Epub 2019 Apr 6.

PMID:
30959157
5.

Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program.

Calvaruso V, Mazzarelli C, Milazzo L, Badia L, Pasulo L, Guaraldi G, Lionetti R, Villa E, Borghi V, Carrai P, Alberti A, Biolato M, Piai G, Persico M, Santantonio T, Felder M, Angelico M, Montalbano M, Mancusi RL, Grieco A, Angeli E, D'Offizi G, Fagiuoli S, Belli L, Verucchi G, Puoti M, Craxì A.

Sci Rep. 2019 Jan 24;9(1):585. doi: 10.1038/s41598-018-36734-0.

6.

Real life experiences in HCV management in 2018.

Viganò M, Andreoni M, Perno CF, Craxì A, Aghemo A, Alberti A, Andreone P, Babudieri S, Bonora S, Brunetto MR, Bruno R, Bruno S, Calvaruso V, Caporaso N, Cartabellotta F, Ceccherini-Silberstein F, Cento V, Ciancio A, Colombatto P, Coppola N, Di Marco V, Di Perri G, Fagiuoli S, Gaeta GB, Gasbarrini A, Lampertico P, Pellicelli A, Prestileo T, Puoti M, Raimondo G, Rizzardini G, Taliani G, Zignego AL.

Expert Rev Anti Infect Ther. 2019 Feb;17(2):117-128. doi: 10.1080/14787210.2019.1563755. Epub 2019 Jan 15. Review.

PMID:
30582384
7.

Predictors of Re-bleeding and Mortality Among Patients with Refractory Variceal Bleeding Undergoing Salvage Transjugular Intrahepatic Portosystemic Shunt (TIPS).

Maimone S, Saffioti F, Filomia R, Alibrandi A, Isgrò G, Calvaruso V, Xirouchakis E, Guerrini GP, Burroughs AK, Tsochatzis E, Patch D.

Dig Dis Sci. 2019 May;64(5):1335-1345. doi: 10.1007/s10620-018-5412-x. Epub 2018 Dec 17.

PMID:
30560334
8.

Suboptimal performance of APRI and FIB-4 in ruling out significant fibrosis and confirming cirrhosis in HIV/HCV co-infected and HCV mono-infected patients.

Mazzola G, Adamoli L, Calvaruso V, Macaluso FS, Colletti P, Mazzola S, Cervo A, Trizzino M, Di Lorenzo F, Iaria C, Prestileo T, Orlando A, Di Marco V, Cascio A.

Infection. 2019 Jun;47(3):409-415. doi: 10.1007/s15010-018-1258-6. Epub 2018 Dec 5.

PMID:
30519966
9.

Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis.

Petta S, Sebastiani G, Bugianesi E, Viganò M, Wong VW, Berzigotti A, Fracanzani AL, Anstee QM, Marra F, Barbara M, Calvaruso V, Cammà C, Di Marco V, Craxì A, de Ledinghen V.

J Hepatol. 2018 Oct;69(4):878-885. doi: 10.1016/j.jhep.2018.05.019. Epub 2018 May 24.

PMID:
29802949
10.

High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma.

Persico M, Aglitti A, Aghemo A, Rendina M, Lleo A, Ciancio A, Di Marco V, Lampertico P, Brunetto MR, Zuin M, Andreone P, Villa E, Troshina G, Calvaruso V, Degasperi E, Coco B, Giorgini A, Conti F, Di Leo A, Marzi L, Boccaccio V, Bollani S, Maisonneuve P, Bruno S.

Aliment Pharmacol Ther. 2018 Jun;47(12):1705-1712. doi: 10.1111/apt.14685. Epub 2018 May 3.

11.

Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.

Calvaruso V, Cabibbo G, Cacciola I, Petta S, Madonia S, Bellia A, Tinè F, Distefano M, Licata A, Giannitrapani L, Prestileo T, Mazzola G, Di Rosolini MA, Larocca L, Bertino G, Digiacomo A, Benanti F, Guarneri L, Averna A, Iacobello C, Magro A, Scalisi I, Cartabellotta F, Savalli F, Barbara M, Davì A, Russello M, Scifo G, Squadrito G, Cammà C, Raimondo G, Craxì A, Di Marco V; Rete Sicilia Selezione Terapia–HCV (RESIST-HCV).

Gastroenterology. 2018 Aug;155(2):411-421.e4. doi: 10.1053/j.gastro.2018.04.008. Epub 2018 Apr 12.

PMID:
29655836
12.

Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis.

Petta S, Adinolfi LE, Fracanzani AL, Rini F, Caldarella R, Calvaruso V, Cammà C, Ciaccio M, Di Marco V, Grimaudo S, Licata A, Marrone A, Nevola R, Pipitone RM, Pinto A, Rinaldi L, Torres D, Tuttolomondo A, Valenti L, Fargion S, Craxì A.

J Hepatol. 2018 Jul;69(1):18-24. doi: 10.1016/j.jhep.2018.02.015. Epub 2018 Mar 2.

PMID:
29505844
13.

Is global elimination of HCV realistic?

Calvaruso V, Petta S, Craxì A.

Liver Int. 2018 Feb;38 Suppl 1:40-46. doi: 10.1111/liv.13668. Review.

PMID:
29427499
14.

Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study.

Lionetti R, Calvaruso V, Piccolo P, Mancusi RL, Mazzarelli C, Fagiuoli S, Montalbano M, Lenci I, Carrai P, Guaraldi G, Visco-Comandini U, Milana M, Biolato M, Loiacono L, Valente G, Craxì A, Angelico M, D'offizi G.

Clin Transplant. 2018 Feb;32(2). doi: 10.1111/ctr.13165. Epub 2017 Dec 18.

PMID:
29193356
15.

Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network.

Kondili LA, Gaeta GB, Brunetto MR, Di Leo A, Iannone A, Santantonio TA, Giammario A, Raimondo G, Filomia R, Coppola C, Amoruso DC, Blanc P, Del Pin B, Chemello L, Cavalletto L, Morisco F, Donnarumma L, Rumi MG, Gasbarrini A, Siciliano M, Massari M, Corsini R, Coco B, Madonia S, Cannizzaro M, Zignego AL, Monti M, Russo FP, Zanetto A, Persico M, Masarone M, Villa E, Bernabucci V, Taliani G, Biliotti E, Chessa L, Pasetto MC, Andreone P, Margotti M, Brancaccio G, Ieluzzi D, Borgia G, Zappulo E, Calvaruso V, Petta S, Falzano L, Quaranta MG, Weimer LE, Rosato S, Vella S, Giannini EG.

PLoS One. 2017 Oct 4;12(10):e0185728. doi: 10.1371/journal.pone.0185728. eCollection 2017.

16.

HBV recurrence after HCV clearance on DAAs: Sometimes they come back.

Calvaruso V, Craxì A.

J Hepatol. 2017 Nov;67(5):898-901. doi: 10.1016/j.jhep.2017.08.017. Epub 2017 Aug 31. No abstract available.

PMID:
28864279
17.

Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study.

Cabibbo G, Petta S, Calvaruso V, Cacciola I, Cannavò MR, Madonia S, Distefano M, Larocca L, Prestileo T, Tinè F, Bertino G, Giannitrapani L, Benanti F, Licata A, Scalisi I, Mazzola G, Cartabellotta F, Alessi N, Barbàra M, Russello M, Scifo G, Squadrito G, Raimondo G, Craxì A, Di Marco V, Cammà C; Rete Sicilia Selezione Terapia - HCV (RESIST-HCV).

Aliment Pharmacol Ther. 2017 Oct;46(7):688-695. doi: 10.1111/apt.14256. Epub 2017 Aug 9.

18.

HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals.

Calvaruso V, Ferraro D, Licata A, Bavetta MG, Petta S, Bronte F, Colomba G, Craxì A, Di Marco V.

J Viral Hepat. 2018 Jan;25(1):72-79. doi: 10.1111/jvh.12754. Epub 2017 Aug 9.

PMID:
28703895
19.

Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens.

Cento V, Nguyen THT, Di Carlo D, Biliotti E, Gianserra L, Lenci I, Di Paolo D, Calvaruso V, Teti E, Cerrone M, Romagnoli D, Melis M, Danieli E, Menzaghi B, Polilli E, Siciliano M, Nicolini LA, Di Biagio A, Magni CF, Bolis M, Antonucci FP, Di Maio VC, Alfieri R, Sarmati L, Casalino P, Bernardini S, Micheli V, Rizzardini G, Parruti G, Quirino T, Puoti M, Babudieri S, D'Arminio Monforte A, Andreoni M, Craxì A, Angelico M, Pasquazzi C, Taliani G, Guedj J, Perno CF, Ceccherini-Silberstein F.

PLoS One. 2017 May 18;12(5):e0177352. doi: 10.1371/journal.pone.0177352. eCollection 2017.

20.

Hepatocellular carcinoma and direct-acting antivirals: A never ending story?

Calvaruso V, Craxì A.

Liver Int. 2017 Jun;37(6):812-814. doi: 10.1111/liv.13421. No abstract available.

PMID:
28544693
21.

Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response.

Bruno S, Di Marco V, Iavarone M, Roffi L, Boccaccio V, Crosignani A, Cabibbo G, Rossi S, Calvaruso V, Aghemo A, Giacomelli L, Craxì A, Colombo M, Maisonneuve P.

Liver Int. 2017 Oct;37(10):1526-1534. doi: 10.1111/liv.13452. Epub 2017 May 20.

PMID:
28418617
22.

A focus on epidemiology of drug-induced liver injury: analysis of a prospective cohort.

Licata A, Minissale MG, Calvaruso V, Craxì A.

Eur Rev Med Pharmacol Sci. 2017 Mar;21(1 Suppl):112-121. Review.

23.

Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies.

Di Maio VC, Cento V, Lenci I, Aragri M, Rossi P, Barbaliscia S, Melis M, Verucchi G, Magni CF, Teti E, Bertoli A, Antonucci F, Bellocchi MC, Micheli V, Masetti C, Landonio S, Francioso S, Santopaolo F, Pellicelli AM, Calvaruso V, Gianserra L, Siciliano M, Romagnoli D, Cozzolongo R, Grieco A, Vecchiet J, Morisco F, Merli M, Brancaccio G, Di Biagio A, Loggi E, Mastroianni CM, Pace Palitti V, Tarquini P, Puoti M, Taliani G, Sarmati L, Picciotto A, Vullo V, Caporaso N, Paoloni M, Pasquazzi C, Rizzardini G, Parruti G, Craxì A, Babudieri S, Andreoni M, Angelico M, Perno CF, Ceccherini-Silberstein F; HCV Italian Resistance Network Study Group.

Liver Int. 2017 Apr;37(4):514-528. doi: 10.1111/liv.13327. Epub 2017 Jan 20.

PMID:
28105744
24.

Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.

van der Meer AJ, Feld JJ, Hofer H, Almasio PL, Calvaruso V, Fernández-Rodríguez CM, Aleman S, Ganne-Carrié N, D'Ambrosio R, Pol S, Trapero-Marugan M, Maan R, Moreno-Otero R, Mallet V, Hultcrantz R, Weiland O, Rutter K, Di Marco V, Alonso S, Bruno S, Colombo M, de Knegt RJ, Veldt BJ, Hansen BE, Janssen HLA.

J Hepatol. 2017 Mar;66(3):485-493. doi: 10.1016/j.jhep.2016.10.017. Epub 2016 Oct 22.

PMID:
27780714
25.

Increased expression of markers of early atherosclerosis in patients with inflammatory bowel disease.

Cappello M, Licata A, Calvaruso V, Bravatà I, Aiello A, Torres D, Della Corte V, Tuttolomondo A, Perticone M, Licata G, Craxì A, Cammà C.

Eur J Intern Med. 2017 Jan;37:83-89. doi: 10.1016/j.ejim.2016.10.004. Epub 2016 Oct 21.

PMID:
27773555
26.

Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis: competing risks and multistate model.

Petta S, Di Marco V, Bruno S, Enea M, Calvaruso V, Boccaccio V, Rossi S, Craxì A, Cammà C.

Liver Int. 2016 Dec;36(12):1765-1773. doi: 10.1111/liv.13156. Epub 2016 Oct 19.

PMID:
27164508
27.

Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population.

Bruno S, Di Marco V, Iavarone M, Roffi L, Crosignani A, Calvaruso V, Aghemo A, Cabibbo G, Viganò M, Boccaccio V, Craxí A, Colombo M, Maisonneuve P.

J Hepatol. 2016 Jun;64(6):1217-23. doi: 10.1016/j.jhep.2016.01.034. Epub 2016 Apr 5.

PMID:
27059129
28.

Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension.

Di Marco V, Calvaruso V, Ferraro D, Bavetta MG, Cabibbo G, Conte E, Cammà C, Grimaudo S, Pipitone RM, Simone F, Peralta S, Arini A, Craxì A.

Gastroenterology. 2016 Jul;151(1):130-139.e2. doi: 10.1053/j.gastro.2016.03.036. Epub 2016 Apr 1.

PMID:
27039970
29.

Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication?

Di Marco V, D'Ambrosio R, Bronte F, Saracco G, Lanza AG, Forni G, Poggiali E, Calvaruso V; on behalf ITHACA (Italy for THAalassemia, hepatitis C Advances) Group.

Dig Liver Dis. 2016 Jun;48(6):650-5. doi: 10.1016/j.dld.2016.02.004. Epub 2016 Feb 21.

PMID:
27012446
30.

Why do I treat my patients with mild hepatitis C?

Calvaruso V, Craxì A.

Liver Int. 2016 Jan;36 Suppl 1:7-12. doi: 10.1111/liv.13011. Review.

PMID:
26725891
31.

Comparison of Histochemical Stainings in Evaluation of Liver Fibrosis and Correlation with Transient Elastography in Chronic Hepatitis.

Cabibi D, Bronte F, Porcasi R, Ingrao S, Giannone AG, Maida M, Grazia Bavetta M, Petta S, Di Marco V, Calvaruso V.

Anal Cell Pathol (Amst). 2015;2015:431750. doi: 10.1155/2015/431750. Epub 2015 Nov 17.

32.

Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis.

Turola E, Petta S, Vanni E, Milosa F, Valenti L, Critelli R, Miele L, Maccio L, Calvaruso V, Fracanzani AL, Bianchini M, Raos N, Bugianesi E, Mercorella S, Di Giovanni M, Craxì A, Fargion S, Grieco A, Cammà C, Cotelli F, Villa E.

Dis Model Mech. 2015 Sep;8(9):1037-46. doi: 10.1242/dmm.019950. Epub 2015 Jul 16.

33.

Residual risk of hepatocellular carcinoma after HCV eradication: more than meets the eye.

Macaluso FS, Calvaruso V, Craxì A.

Future Microbiol. 2015;10(6):977-88. doi: 10.2217/fmb.15.31. Review.

PMID:
26059621
34.

Comparison of Histochemical Staining Methods and Correlation with Transient Elastography in Acute Hepatitis.

Cabibi D, Calvaruso V, Giuffrida L, Ingrao S, Balsamo L, Giannone AG, Petta S, Di Marco V.

Pathobiology. 2015;82(1):48-52. Epub 2015 Mar 6.

35.

Quantification of fibrosis by collagen proportionate area predicts hepatic decompensation in hepatitis C cirrhosis.

Calvaruso V, Di Marco V, Bavetta MG, Cabibi D, Conte E, Bronte F, Simone F, Burroughs AK, Craxì A.

Aliment Pharmacol Ther. 2015 Mar;41(5):477-86. doi: 10.1111/apt.13051. Epub 2015 Jan 11.

36.

Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis.

Maasoumy B, Hunyady B, Calvaruso V, Makara M, Vermehren J, Haragh A, Susser S, Bremer B, Cloherty G, Manns MP, Craxì A, Wedemeyer H, Sarrazin C.

PLoS One. 2014 Nov 12;9(11):e110857. doi: 10.1371/journal.pone.0110857. eCollection 2014.

37.

Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program.

Bruno S, Bollani S, Zignego AL, Pascasio JM, Magni C, Ciancio A, Caremani M, Mangia A, Marenco S, Piovesan S, Chemello L, Babudieri S, Moretti A, Gea F, Colletta C, Perez-Alvarez R, Forns X, Larrubia JR, Arenas J, Crespo J, Calvaruso V, Ceccherini Silberstein F, Maisonneuve P, Craxì A, Calleja JL; Italian and Spanish (IAS)-BoC Study Group.

J Viral Hepat. 2015 May;22(5):469-80. doi: 10.1111/jvh.12342. Epub 2014 Oct 14.

38.

Clinical implications of the hyperdynamic syndrome in cirrhosis.

Licata A, Mazzola A, Ingrassia D, Calvaruso V, Cammà C, Craxì A.

Eur J Intern Med. 2014 Nov;25(9):795-802. doi: 10.1016/j.ejim.2014.09.004. Epub 2014 Sep 20. Review.

PMID:
25245607
39.

An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C.

Andriulli A, Nardi A, Di Marco V, Ippolito AM, Gavrila C, Aghemo A, Di Paolo D, Squadrito G, Grassi E, Calvaruso V, Valvano MR, Brancaccio G, Craxi A, Angelico M; Collaborators.

Dig Liver Dis. 2014 Sep;46(9):818-25. doi: 10.1016/j.dld.2014.05.015. Epub 2014 Jun 20.

PMID:
24953209
40.

Immunological alterations in hepatitis C virus infection.

Calvaruso V, Craxì A.

World J Gastroenterol. 2013 Dec 21;19(47):8916-23. doi: 10.3748/wjg.v19.i47.8916. Review.

41.

Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible?

Calvaruso V, Craxì A.

Liver Int. 2014 Feb;34 Suppl 1:85-90. doi: 10.1111/liv.12395. Review.

PMID:
24373083
42.

Modified spleen stiffness measurement by transient elastography is associated with presence of large oesophageal varices in patients with compensated hepatitis C virus cirrhosis.

Calvaruso V, Bronte F, Conte E, Simone F, Craxì A, Di Marco V.

J Viral Hepat. 2013 Dec;20(12):867-74. doi: 10.1111/jvh.12114. Epub 2013 Aug 12.

PMID:
24304456
43.

Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis.

Di Marco V, Covolo L, Calvaruso V, Levrero M, Puoti M, Suter F, Gaeta GB, Ferrari C, Raimondo G, Fattovich G, Santantonio T, Alberti A, Bruno R, Mussini C, Mondelli M, Donato F, Craxì A; Multicenter Italian Group for the Study of Hepatitis C.

J Viral Hepat. 2013 Nov;20(11):790-800. doi: 10.1111/jvh.12106. Epub 2013 Sep 15.

PMID:
24168258
44.

Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin.

Andriulli A, Di Marco V, Margaglione M, Ippolito AM, Fattovich G, Smedile A, Valvano MR, Calvaruso V, Gioffreda D, Milella M, Morisco F, Felder M, Brancaccio G, Fasano M, Gatti P, Tundo P, Barone M, Cozzolongo R, Angelico M, D'Andrea G, Andriulli N, Abate ML, Mazzella G, Gaeta GB, Craxi A, Santantonio T.

J Hepatol. 2014 Jan;60(1):16-21. doi: 10.1016/j.jhep.2013.07.040. Epub 2013 Aug 20.

45.

Fibrosis evaluation by transient elastography in patients with long-term sustained HCV clearance.

Calvaruso V, Di Marco V, Ferraro D, Petta S, Calì A, Grazia Bavetta M, Conte E, Luigi Almasio P.

Hepat Mon. 2013 May 11;13(5):e7176. doi: 10.5812/hepatmon.7176. eCollection 2013 May.

46.

NT pro BNP plasma level and atrial volume are linked to the severity of liver cirrhosis.

Licata A, Corrao S, Petta S, Genco C, Cardillo M, Calvaruso V, Cabibbo G, Massenti F, Cammà C, Licata G, Craxì A.

PLoS One. 2013 Aug 5;8(8):e68364. doi: 10.1371/journal.pone.0068364. Print 2013.

47.

Anisakiasis and gastroallergic reactions associated with Anisakis pegreffii infection, Italy.

Mattiucci S, Fazii P, De Rosa A, Paoletti M, Megna AS, Glielmo A, De Angelis M, Costa A, Meucci C, Calvaruso V, Sorrentini I, Palma G, Bruschi F, Nascetti G.

Emerg Infect Dis. 2013 Mar;19(3):496-9. doi: 10.3201/eid1903.121017.

48.

Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices.

Di Marco V, Calvaruso V, Grimaudo S, Ferraro D, Pipitone RM, Di Stefano R, Craxì A.

J Viral Hepat. 2013 Feb;20(2):113-21. doi: 10.1111/j.1365-2893.2012.01637.x. Epub 2012 Jul 25.

PMID:
23301546
49.

Digital image analysis of collagen assessment of progression of fibrosis in recurrent HCV after liver transplantation.

Manousou P, Burroughs AK, Tsochatzis E, Isgro G, Hall A, Green A, Calvaruso V, Ma GL, Gale J, Burgess G, O'Beirne J, Patch D, Thorburn D, Leandro G, Dhillon AP.

J Hepatol. 2013 May;58(5):962-8. doi: 10.1016/j.jhep.2012.12.016. Epub 2012 Dec 20. Erratum in: J Hepatol. 2013 Aug;59(2):402. Sochatzis, Emmanuel T [corrected to Tsochatzis, Emmanuel].

PMID:
23262247
50.

The relationship between transient elastography and histological collagen proportionate area for assessing fibrosis in chronic viral hepatitis.

Isgro G, Calvaruso V, Andreana L, Luong TV, Garcovich M, Manousou P, Alibrandi A, Maimone S, Marelli L, Davies N, Patch D, Dhillon AP, Burroughs AK.

J Gastroenterol. 2013 Aug;48(8):921-9. doi: 10.1007/s00535-012-0694-9. Epub 2012 Nov 3.

PMID:
23124603

Supplemental Content

Loading ...
Support Center